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High blood concentration of the N-terminal cleavage product of the B-type natriuretic peptide (NT-proBNP) is
strongly associated with cardiac dysfunction and is increasingly used for heart failure diagnosis. To identify
genetic variants associated with NT-proBNP level, we performed a genome-wide association analysis in 1325
individuals from South Tyrol, Italy, and followed up the most significant results in 1746 individuals from two
German population-based studies. A genome-wide significant signal in the MTHFR-CLCN6-NPPA-NPPB gene
cluster was replicated, after correction for multiple testing (replication one-sided P-value 5 8.4 3 10210). A
conditional regression analysis of 128 single-nucleotide polymorphisms in the region of interest identified
novel variants in the CLCN6 gene as independently associated with NT-proBNP. In this locus, four haplotypes
were associated with increased NT-proBNP levels (haplotype-specific combined P-values from 8.3 3 10203 to
9.3 3 10211). The observed increase in the NT-proBNP level was proportional to the number of haplotype
copies present (i.e. dosage effect), with an increase associated with two copies that varied between 20 and
100 pg/ml across populations.The identification of novel variants in the MTHFR-CLCN6-NPPA-NPPB cluster
provides new insights into the biological mechanisms of cardiac dysfunction.
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INTRODUCTION
NT-proBNP is the N-terminal signal peptide of pro-B-type
natriuretic peptide (proBNP). ProBNP is synthesized in the
heart as a reaction to increased wall distension, neurohormonal
and immunological activation (1–4), and splits into BNP and
NT-proBNP upon secretion from the cardiomyocyte. Although
BNP and NT-proBNP, which have both emerged as important
markers of cardiac function, have a common genetic precur-
sor, blood concentrations of NT-proBNP differ markedly
from and exceed those of BNP due to differential clearance
mechanisms and a longer half-life (5–10).
Previously, an important role of genetic factors in the
regulation of blood BNP level was suggested by a heritability
estimate of 0.35, reported from a study of 1914 individuals
of Caucasian origin (11). A similar estimate was obtained
for NT-proBNP in 1325 individuals from our MICROS
(Microisolates in South Tyrol) study in South Tyrol (data
not published). A genome-wide association (GWA) analysis
of BNP in the Framingham Heart Study (12) identified
only one locus for BNP regulation, the nuclear factor I/A
(NFIA) gene, expressed in the heart, which has not yet
been replicated. No GWA analysis of NT-proBNP has been
reported yet. Candidate gene studies revealed a significant
association of NT-proBNP with its precursor gene NPPB,
encoding the proBNP, in 164 normo-albuminuric type 1 dia-
betic patients (13) as well as with the natriuretic peptide pre-
cursor A (NPPA) gene, both in healthy individuals (14) and
in patients with severe heart failure (15). These results were
confirmed in a meta-analysis of 14 473 samples of European
ancestry, which showed a strong association of variants in
the NPPB and NPPA genes with BNP and NT-proBNP
levels (16).
To improve our comprehension of genetic variants influen-
cing the complex biology of the natriuretic peptide system, to
identify potential genetic modifiers of cardiac hormonal
response to increased wall stress and to better understand the
genetic contribution to NT-proBNP serum concentration by
identifying additional genetic variants involved in this
system, we performed a GWA study of NT-proBNP blood
level in 1325 individuals from the MICROS study, a
population-based genetic survey of three semi-isolated
Alpine villages in northern Italy (17). Results from this analy-
sis were subsequently assessed for possible replication in two
independent population-based studies from southern and
northern Germany, namely KORA-F3 (from the MONICA/
KORA study) and popgen.
RESULTS
GWA and replication analyses
Characteristics of the study samples are reported in Table 1. The
mean NT-proBNP level was 102.5 (standard deviation, SD¼
365.0), 96.1 (SD¼ 171.2) and 144.3 (SD¼ 240.4) pg/ml in
MICROS, popgen and KORA-F3, respectively. The
Manhattan plot of the discovery GWA analysis in MICROS is
given in Figure 1A together with the quantile–quantile (QQ)
plot to illustrate the level of potential P-value inflation
(Fig. 1B). The genomic control factor (l) was 0.99, indicating
that no cryptic relatedness or hidden population structure
affected our GWA results. To account for multiple testing,
the significance threshold in the GWA analysis was set
to 7.2 × 10– 8 (18). Two genome-wide significant hits were
observed, namely for SNPs rs1023252, located within the
chloride channel 6 (CLCN6) gene (P-value ¼ 3.7 × 10208),
and rs1004565, located close to the odz, odd Oz/ten-m
homolog 4 (Drosophila) (ODZ4) gene (P-value¼ 5.3 × 10208)
(Table 2).
To assess the possible impact of pharmacological treatment
upon our GWA results, sensitivity analyses were performed
where individuals taking drugs potentially affecting the
Table 1. Characteristics of study samples [mean (SD) unless otherwise specified]
Study name MICROS (Discovery study) popgen (Replication study) KORA-F3 (Replication study)
Number of samples, n (%) 1325 (100) 1152 (100) 594 (100)
Females, n (%) 749 (57) 512 (44) 325 (55)
Age (years) 45 (17) 57 (14) 62 (10)
NT-proBNP (pg/ml)
Median (range) 45.6 (20.0–8116.0) 48.4 (4.9–2304.0) 77.6 (7.2–2504.0)
Distribution, n (%)
,20 241 (18.2) 194 (16.8) 28 (4.7)
20–125 911 (68.7) 754 (65.4) 384 (64.7)
125–300 124 (9.3) 144 (12.5) 127 (21.4)
.300 49 (3.7) 60 (5.2) 55 (9.3)
BMI 24.7 (4.8) 26.3 (4.4) 27.6 (4.2)
DBP (mmHg) 79.5 (11.4) 80.9 (9.5) 82.7 (17.4)
SBP (mmHg) 132.5 (20.6) 134.9 (17.3) 131.9 (21.1)
Hypertensiona, n (%) 452 (36.5) 537 (46.9) 364 (61.3)
Strokeb, n (%) 19 (1.4) 25 (2.2) 14 (2.3)
Myocardial infarctionb, n (%) 16 (1.2) 33 (2.9) 15 (2.5)
Atrial fibrillationb, n (%) 6 (0.4) 13 (1.2) Not available
SD, standard deviation; DBP, diastolic blood pressure; SBP, systolic blood pressure; BMI, body mass index.
aDefined as SBP ≥140 mmHg or DBP ≥90 mmHg or under treatment for hypertension.
bAssessed by questionnaire interview.
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NT-proBNP level were removed from the analysis (details are
given in Materials and Methods). Results from these sensi-
tivity analyses did not differ from those of the main GWA
analysis.
Twenty-five SNPs with P-values ,10205 were selected for
replication, provided that at least another SNP with P-value
,10204 was located within 100 kb and that the power to repli-
cate, when accounting for multiple testing, was ≥80%. The
SNPs were chosen to represent independent loci, with inde-
pendency defined as pair-wise r2 value ,0.2 (see Materials
and Methods). Among these, the power to replicate, after
accounting for multiple testing, ranged from 82 to 99%. The
replication analysis was performed separately in popgen
and KORA-F3, and the results were pooled using an
inverse-variance-weighted fixed-effect meta-analysis. We con-
sidered a locus to be replicated when the effect direction was
the same in the discovery and replication analyses, and the
corresponding one-sided replication P-value was ≤0.002
(i.e. Bonferroni correction). Results of both the discovery
and the replication analyses are reported in Table 2. Also
included are the results of a joint analysis of all discovery
and replication samples, using an inverse-variance-weighted
fixed-effect meta-analysis as well.
The association between rs1023252 and loge(NT-proBNP)
observed in the GWA analysis was replicated in the German
samples (one-sided P-value ¼ 8.4 × 10– 10), with an effect in
the replication analysis that was remarkably similar to that
of the discovery analysis (Table 2). In the combined analysis,
the effect of the SNP was 0.20 loge pg/ml per allele
(P-value ¼ 3.5 × 10– 16). This SNP identifies a locus that, in
addition to the CLCN6 gene, also includes the methylenetetra-
hydrofolate reductase (MTHFR) gene, the NPPA gene and the
NPPB gene. Given the high level of linkage disequilibrium
(LD) within the MTHFR-CLCN6-NPPA-NPPB gene cluster,
we investigated the whole locus using conditional single-
marker and haplotype analyses (see what follows) to assess
whether the signal in the CLCN6 gene was independent
from that of the NPPB gene, the obvious biological candidate
for regulating the NT-proBNP level.
Three additional SNPs, although not surviving the Bonfer-
roni correction in the replication analysis, were found to be
associated with NT-proBNP in the replication analysis at a
Figure 1. (A) Manhattan plot of the results of the GWA analysis in the MICROS study. The locus marked in red satisfied the replication criterion. (B) The QQ
plot in the upper-right corner compares expected versus observed –log10(P-value) for all 2.5 million SNPs included in the GWA analysis, with the dashed line
corresponding to the null hypothesis of no association.
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nominal significance level of 0.05 and with effect in the same
direction as in the discovery analysis, namely rs3919597 (one-
sided P-value ¼ 0.026), rs4869419 (one-sided P-value ¼
0.014) and rs6009824 (one-sided P-value ¼ 0.032). SNP
rs3919597 is located 239 kb downstream of the Meis homeo-
box 1 (MEIS1) gene, rs4869419 is located close to the
chaperonin-containing TCP1, subunit 7 (eta) pseudogene 2
(CCT7P2) and 362 kb upstream of the nuclear receptor
subfamily 2, group F, member 1 (NR2F1) gene, and
rs6009824 is located nearby the bromodomain-containing
protein 1 (BRD1) gene. Finally, despite an estimated replica-
tion power of 99% and a genome-wide significant P-value in
the discovery phase, rs1004565 close to the ODZ4 gene did
not replicate.
These results remained unchanged in a sample-size-weighted
meta-analysis based on the Z-score method, which pools study-
specific P-values accounting for effect direction and is robust to
differences between phenotype measurement methods. There-
fore, our findings were unlikely to be affected by differences
in effect size due to the use of a different laboratory assay in
MICROS compared with the two German studies (results not
shown).
Investigation of the MTHFR-CLCN6-NPPA-NPPB locus
The four genes in the MTHFR-CLCN6-NPPA-NPPB locus are
located within the 121 kb region on chromosome 1 (Fig. 2). To
investigate whether different variants in this locus were inde-
pendently associated with the NT-proBNP level, we selected
all 128 SNPs available for a thorough analysis. Results of
the combined analysis of the discovery and replication
samples for these SNPs, together with information on LD
and gene location, are given in Figure 2 (for additional
details, see Supplementary Material, Table S1). The smallest
P-values were obtained for two SNPs in the NPPB gene,
rs6668352 (P-value ¼ 1.7 × 10– 18) and rs12406383
(P-value¼ 3.7× 10–18), although both associations were
characterized by strong heterogeneity between studies with I2
values of 53 and 56%, respectively (Fig. 2). Other SNPs
located either in the promoter region of the NPPB gene
(rs12406089, P-value¼ 3.5× 10–16; rs6668659, P-value¼
5.3× 10–16), in the CLCN6 gene (rs1023252, P-value¼ 3.2×
10–16) or in the MTHFR gene (rs12121543, P-value¼ 1.8×
10–15; rs3818762, P-value¼ 3.1× 10–14) showed strong
associations, and the effects were homogeneous across studies.
Table 2. SNPs selected for replication by chromosome and position: results of the discovery, replication and combined analyses
SNPs selected from the discovery analysis for replication Discovery analysis
(MICROS)
Replication analysis
(meta-analysis of data
from popgen and
KORA-F3)
Combined analysis
(meta-analysis of data from
MICROS, popgen and
KORA-F3)
SNP ID Chr Position (NCBI
build 36)
Gene annotation
(distance to nearest
gene)
Major/
minor
allelesa
MAFb Effect (SE) P-valuec Effect (SE) One-sided
P-valued
Effect (SE) P-value
rs1023252 1 11 821 620 CLCN6 (intronic) G/T 0.26 0.21 (0.04) 3.7 × 10208 0.20 (0.03) 8.4 × 10210 0.20 (0.02) 3.5 × 10216
rs10927698 1 15 376 990 TMEM51 (intronic) T/G 0.39 20.16 (0.03) 2.1 × 10206 20.02 (0.03) 0.275 20.08 (0.02) 2.9 × 10204
rs7547072 1 152 905 879 ADAR (38 kb) C/T 0.48 0.13 (0.03) 8.7 × 10205 20.01 (0.03) 0.653 0.06 (0.02) 0.014
rs10864721 1 230 340 755 DISC1 (97 kb) G/C 0.18 0.19 (0.04) 1.4 × 10206 20.05 (0.04) 0.907 0.06 (0.03) 0.019
rs3919597 2 66 882 384 MEIS1 (239 kb) C/T 0.47 0.13 (0.03) 3.0 × 10205 0.06 (0.03) 0.026 0.09 (0.02) 1.7 × 10205
rs1921649 2 223 977 434 SCG2 (192 kb) G/A 0.47 20.15 (0.03) 2.5 × 10205 20.03 (0.03) 0.171 20.08 (0.02) 3.5 × 10204
rs1919008 3 108 312 022 CCDC54 (266 kb) C/A 0.14 0.23 (0.05) 1.2 × 10205 20.08 (0.04) 0.957 0.05 (0.03) 0.139
rs16842453 3 136 197 466 EPHB1 (intronic) G/C 0.06 20.30 (0.07) 5.1 × 10205 20.06 (0.06) 0.144 20.15 (0.04) 8.8 × 10204
rs7669710 4 26 982 314 STIM2 (346 kb) G/A 0.43 0.14 (0.03) 3.9 × 10205 0.05 (0.03) 0.064 0.09 (0.02) 8.7 × 10205
rs17071059 4 182 471 437 ODZ3 (101 kb) T/C 0.15 20.18 (0.05) 7.4 × 10205 0.06 (0.04) 0.944 20.04 (0.03) 0.155
rs4869419 5 92 593 295 CCT7P2 (34 kb) A/G 0.08 20.25 (0.06) 2.1 × 10205 20.14 (0.06) 0.014 20.20 (0.04) 3.8 × 10206
rs9294233 6 82 327 882 FAM46A (184 kb) A/G 0.31 20.14 (0.03) 7.3 × 10205 0.00 (0.03) 0.522 20.06 (0.02) 0.008
rs12533743 7 24 435 064 NPY (137 kb) T/C 0.38 20.14 (0.03) 4.9 × 10205 20.01 (0.03) 0.399 20.07 (0.02) 0.002
rs7820107 8 93 765 031 RUNX1T1 (588 kb) T/C 0.04 0.32 (0.08) 4.4 × 10205 0.07 (0.09) 0.199 0.21 (0.06) 3.2 × 10204
rs396250 9 105 127 157 CYLC2 (306 kb) G/A 0.10 0.21 (0.05) 6.5 × 10205 20.12 (0.05) 0.993 20.03 (0.04) 0.340
rs1004565 11 79 055 348 ODZ4 (597 kb) C/T 0.02 0.82 (0.15) 5.3 × 10208 20.19 (0.11) 0.955 20.18 (0.09) 0.054
rs11226914 11 105 446 714 KBTBD3 (intronic) T/G 0.02 0.45 (0.11) 3.2 × 10205 20.06 (0.14) 0.669 0.26 (0.09) 0.002
rs10845158 12 10 580 021 KLRA1 (52 kb) C/G 0.33 0.16 (0.04) 8.7 × 10206 0.00 (0.03) 0.496 0.08 (0.02) 0.002
rs10847578 12 127 272 840 TMEM132C (393 kb) T/C 0.49 0.15 (0.03) 1.8 × 10205 20.03 (0.03) 0.815 0.05 (0.02) 0.031
rs9510008 13 21 637 260 FGF9 (463 kb) C/T 0.10 20.22 (0.06) 8.4 × 10205 20.08 (0.08) 0.148 20.17 (0.04) 1.5 × 10204
rs12920706 16 22 638 484 HS3ST2 (94 kb) T/C 0.43 0.19 (0.04) 1.2 × 10205 0.01 (0.03) 0.401 0.07 (0.03) 0.005
rs9940021 16 26 204 097 HS3ST4 (149 kb) G/T 0.48 0.13 (0.03) 3.2 × 10205 20.01 (0.03) 0.577 0.06 (0.02) 0.006
rs1943064 16 73 547 505 WDR59 (intronic) C/T 0.39 0.14 (0.03) 2.8 × 10205 20.09 (0.03) 0.998 20.02 (0.02) 0.458
rs9620688 22 26 109 122 MN1 (365 kb) G/A 0.32 0.13 (0.03) 9.8 × 10205 0.03 (0.04) 0.234 0.09 (0.03) 6.1 × 10204
rs6009824 22 48 472 377 BRD1 (81 kb) G/A 0.15 20.18 (0.04) 6.3 × 10206 20.08 (0.04) 0.032 20.13 (0.03) 6.7 × 10206
aThe reference allele for association analysis is always the minor allele.
bMAF: minor allele frequency as estimated by the sample-size-weighted mean of individual study MAFs.
cIn bold, genome-wide significant P-values.
dIn bold, P-values ≤threshold for replication; threshold for replication was set to 0.002, i.e. the nominal level of 0.05 divided by 25 independent tests (Bonferroni
correction for multiple testing); in italics, P-values ≤0.05.
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From the 128 SNPs available in the locus of interest, we
selected 22 (highlighted in grey in Supplementary Material,
Table S1) that were genotyped in at least one study and had
high genotype imputation quality (Rsq. 0.6) in the others
(see Materials and Methods and Supplementary Material,
Table S2). To assess which of these SNPs were independently
associated with NT-proBNP, we performed a conditional
regression analysis of individual SNP, adjusting for the
effect of SNPs in other genes by including one gene at a
time into the model. Effects were then pooled over studies,
using an inverse-variance-weighted fixed-effect meta-analysis,
and results are presented in Figure 3. Only one SNP was found
to be associated with NT-proBNP independently from the
other genes’ variants, namely rs1023252 in the CLCN6 gene,
which showed a strong trait association even after adjustment
for SNPs in the NPPB gene.
Another SNP, rs5063 in the NPPA gene, showed a trait
association that was independent from that of SNPs in the
NPPB gene, but not from that of SNPs in CLCN6 or
MTHFR. Marker rs5063 is in high LD (r2. 0.98) with two
SNPs in the CLCN6 gene, rs2075538 and rs2075539, which
are adjacent to rs1023252 (see above). This implies that var-
iants located in the CLCN6 and/or in the NPPA genes could
be related to NT-proBNP independently of the NPPB gene.
The association of SNPs in the MTHFR gene with NT-proBNP
disappeared upon adjustment for SNPs in the NPPB or CLCN6
gene. Finally, adjustment for SNPs in the NPPA gene had no
major influence on the association between NT-proBNP and
SNPs in the other three genes.
Among the 22 SNPs more closely investigated in the four-
gene cluster, rs1023252 in the CLCN6 was the best predictor
of the NT-proBNP level, explaining 2.9% of the trait variance
in MICROS, 2.2% in popgen, 0.5% in KORA-F3 and 2.1% in
the overall sample. Among the SNPs in the NPPB domain,
rs6676300 was the most predictive one, explaining 2.0, 2.1
and 0.3% of the trait variance, in MICROS, popgen and
KORA-F3, respectively (1.7% overall). When including all
SNPs from the same gene domain in the model, the largest
proportion of variance was explained by SNPs in the
CLCN6 domain (2.1% overall). SNPs in the NPPB domain
explained 1.9%. When all SNPs in the whole locus in the
same model were included, we were able to explain 2.4% of
the total variance. Additional details are provided in Sup-
plementary Material, Table S3. In general, we observed that
the proportion of variance explained by the genetic variants
of the gene cluster was smaller in the KORA-F3 study
sample, compared with MICROS or popgen. We investigated
whether the low variance explained in KORA-F3 might have
been due to a problem of genotype measurement error due
to the lower average imputation quality (median Rsq ¼ 0.68
versus Rsq ¼ 0.95 and 0.99 in MICROS and popgen, respect-
ively). The data did not support this hypothesis since the var-
iance explained by individual SNPs in KORA-F3 was very
low also for SNPs which were either genotyped or imputed
with high quality (see Supplementary Material, Tables S2
and S3). A more convincing explanation could be the older
age of KORA-F3 participants, with age being a strong predic-
tor of the NT-proBNP level. In fact, adding age and sex to the
model with the 22 SNPs led to a variance explained in
KORA-F3 similar to that of popgen (24.3 versus 24.9%).
Given that SNPs in the MTHFR, CLCN6 and NPPA
genes provided additional information to predict the
NT-proBNP level compared with studying variants in the
NPPB gene alone, we further explored the associations
between NT-proBNP and genetic variation in the
MTHFR-CLCN6-NPPA-NPPB gene locus by performing a
haplotype analysis of the 22 selected SNPs. Haplotype
effects were again pooled across the three studies using an
inverse-variance-weighted fixed-effect meta-analysis. Four
haplotypes were consistently found to be associated with
Figure 2. Results of the inverse-variance-weighted fixed-effect meta-analysis
of the discovery and replication studies (combined analysis) on the
MTHFR-CLCN6-NPPA-NPPB gene cluster on chromosome 1. Upper panel:
Plot of –log10(P-values) against SNP physical position; the density of the col-
ouring indicates the between-study heterogeneity of the effect size estimates,
based on the I2 statistics. Heterogeneity is classified into four categories: null
or low (I2≤ 25%), moderate (25%, I2≤ 50%), high (50%, I2≤ 75%) and
very high (I2. 75%) (44). The recombination intensity was estimated from
phased haplotypes in HapMap Release 22 (NCBI build 36) (45), and is
reported as a light-grey line. Middle panel: LD (r2) in the HapMap-CEU popu-
lation Release 22 (NCBI build 36). Colours vary between white (r2¼ 0) and
black (r2¼ 1). Lower panel: Structure of the four genes in the locus according
to the UCSC Table browser (46), which is based on NCBI build 36. This graph
was in part created using utilities from the SNAP software (47).
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Figure 3. Haplotype distribution of the 22 SNPs selected for haplotype analysis of the MTHFR-CLCN6-NPPA-NPPB gene cluster. Different colours were used to
distinguish the four genes. In the ‘haplotype’ panel, alleles that differ from the reference haplotype alleles are highlighted in yellow. In the ‘adjusted for’ panel,
the P-values of the conditional association analysis are reported. Significant associations (P-values ≤ 0.003, see Materials and Methods) are highlighted in bold
on an orange background. In the diagonal cells, results of the unadjusted association between NT-proBNP and the SNP in the relative column are reported. Out of
the diagonal, results from conditional analyses are reported, where association at each particular variant is adjusted for SNPs in the gene indicated on the left side
of the figure. In the right panel, study-specific haplotype frequencies and results of the haplotype association analysis are reported, with significant P-values given
in bold. In the bottom panel, the LD structure (r2) for the three studies is reported.
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loge(NT-proBNP) in all studies, with pooled effect estimates
ranging from 0.19 to 0.43 loge(pg/ml), and with P-values
between 8.3 × 10203 and 9.3 × 10– 11 (Fig. 3). A fifth haplo-
type showed borderline association (effect ¼ 0.15, P-value ¼
0.074) with loge(NT-proBNP). All five haplotypes were
characterized by a G allele for SNP rs6676300, which is
located near the promoter region of the NPPB gene.
However, other haplotypes carrying this allele were not
associated with the trait (Fig. 3), suggesting that more
complex genotype combinations could affect the NT-proBNP
level.
Figure 4 highlights the extent of the genetically derived
differences in NT-proBNP concentrations showing the levels
for subjects carrying one or two of the four significantly
associated haplotypes. It can be seen that NT-proBNP levels
increase with increasing number of haplotype copies. In
MICROS, the median NT-proBNP level of individuals
lacking two haplotypes was 43 pg/ml, compared with 64 pg/ml
for individuals with two copies. The corresponding figures in
the German samples were 45 versus 66 pg/ml (popgen) and
75 versus 178 pg/ml (KORA-F3), respectively. NT-proBNP
variability also increased with an increasing number of haplo-
types.
DISCUSSION
Our GWA analysis of serum NT-proBNP levels identified an
association with a cluster of four genes, MTHFR, CLCN6,
NPPA and NPPB, and this result was replicated in a
meta-analysis of two independent German samples. Con-
ditional analyses highlighted a signal in CLCN6 independent
from the NPPB signal. Four haplotypes spanning these
genes were found to be significantly associated with
NT-proBNP. These haplotypes showed a dosage effect in
that the NT-proBNP level tended to increase with an increas-
ing number of copies carried by an individual.
In an earlier candidate gene study of the BNP pathway,
polymorphisms in the NPPB gene were found to be associated
with a considerable variation in the BNP level, explaining up
to 6% of the trait variability in patients undergoing elective
cardiac catheterization (19). Two polymorphisms of the
NPPB gene, rs198389 and rs198388, have been reported
as being associated with NT-proBNP levels in 164
normo-albuminuric type 1 diabetic (13). In another study, a
4-polymorphism haplotype in the NPPA gene turned out to
be associated with the NT-proBNP level of healthy individ-
uals, although this association was not seen in patients with
either heart failure or acute coronary syndrome (14). In con-
trast, Vassalle et al. (15) found an association between an
ScaI polymorphism in the NPPA gene (corresponding to
rs5065) and ANP, BNP and NT-proBNP levels in their
sample of severe heart failure patients. In our study, we
could not replicate the trait association of rs5065 but found
an association with a nearby SNP rs5063 that was partially
independent from the NPPB variants. Associations between
ANP and BNP level, respectively, and polymorphisms in the
NPPA and NPPB genes were also reported by Newton-Cheh
et al. (16), in a study including the Framingham Heart
Study, the Finrisk1997 Study and the Malmo¨ Diet and
Cancer Study (MDCS). We confirmed the association
between rs632793 in the NPPA domain and NT-proBNP
observed in the MDCS study, with effect size of very
similar magnitude (0.13 log pg/ml, P-value ¼ 1 × 10209 in
MDCS versus 0.16, P-value ¼ 3.6 × 10208 in our study).
The same SNP was also strongly associated with the BNP in
all other studies. We could not replicate the association with
rs5068 found in MDCS. The CLCN6 SNP rs1023252 was
not associated with the BNP in the Framingham Heart
Study, but the association with NT-proBNP was not evaluated.
Evidence from all these earlier studies supports, in a very
consistent way, an association between polymorphisms in
the NPPB and NPPA genes and NT-proBNP levels.
However, the four genes in the MTHFR-CLCN6-NPPA-NPPB
Figure 4. Study-specific distribution of (untransformed) NT-proBNP levels by number of significantly associated haplotypes, carried by the subject. 0: no copies;
1, 2: one or two copies of any significant haplotype. The number of individuals per category is indicated within the boxes; the median NT-proBNP level (pg/ml)
is reported close to the black horizontal line in the middle of the box.
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locus are in LD with each other, and so, investigation of any of
these genes should control for the effects of the other genes.
For example, a study on Korean individuals reported a
strong association between the MTHFR C688T variant and
plasma BNP levels (20), but there was no control for NPPA
or NPPB gene variants. Thus, the suggested prognostic value
of the MTHFR C677T variant for BNP concentration could
reflect, indirectly, variants located in one of the other genes
in the locus.
A similar situation has been observed when investigating
blood pressure. Newton-Cheh et al. (16) showed that poly-
morphisms in the NPPB and NPPA genes associated with
BNP levels were also associated with blood pressure and
hypertension. In a meta-analysis of GWA studies on blood
pressure, the same authors observed that the SNP most
strongly associated with systolic blood pressure, among all
available variants in the four-gene locus, was located in the
MTHFR gene but discussed the difficulty to dissect which of
the genes in the locus could be responsible for blood pressure
variations (21).
Conditional analyses, where the association between a
genetic variant in one gene is adjusted for variants located
in the other genes, can help understand the complex
picture by disentangling the effects of correlated gene var-
iants. Haplotype analysis can, on the other hand, provide a
comprehensive view of the complexity of the gene cluster.
The results of our conditional analyses suggest that the
association between NT-proBNP and variants in the
MTHFR gene observed in our GWA analysis might reflect
the trait association of variants in the CLCN6 and NPPB
genes. On the contrary, the association of the SNP
rs1023252 in the CLCN6 gene appeared to be mostly inde-
pendent from variants in all nearby genes, including NPPB.
Three other variants in complete LD with each other
(rs5063 in NPPA and rs2075538 and rs2075539 in CLCN6)
were associated with NT-proBNP levels independently from
SNPs in NPPB.
The independency of the signals in theCLCN6 gene shown by
our conditional analyses suggests a role of this gene in the regu-
lation of NT-proBNP, which has not been hypothesized pre-
viously. CLCN6 gene function has been poorly understood so
far. What is known is that the gene encodes one of several
voltage-gated chloride channels (CLC-6), which is predomi-
nantly located in intracellular membranes and is widely
expressed in various tissues (22). Gene targeting and transgenic
animal models have been used to delineate the functional role of
cardiac chloride channels in the context of health and disease. In
general, it has been shown that chloride channels may contribute
to cardiac arrhythmogenesis, myocardial hypertrophy, heart
failure and cardioprotection against ischaemia/reperfusion
(23). Although this evidence points towards association with
cardiovascular phenotypes, no direct link between BNP or
NT-proBNP and voltage-gated chloride channels, including
CLC-6, has been shown so far. The findings from our study
suggest the hypothesis of a role of the CLCN6 gene in the regu-
lation of NT-proBNP either directly or indirectly by modifying
NPPB gene expression. However, we cannot exclude the possi-
bility that the CLCN6 variants identified in our study, in particu-
lar rs1023252, may be simply markers in LD with an
unobserved causal variant located inside the NPPB gene
domain, or indeed may be more directly involved in long-range
regulation of NPPB expression.
To capture the effect of the combination of variants in the
MTHFR-CLCN6-NPPA-NPPB gene cluster, we estimated
haplotypes using the 22 best SNPs available in the locus
(i.e. those that were genotyped in at least one study and had
high imputation quality in the others), and we were able to
estimate reliable haplotypes. Four different haplotypes were
associated with higher NT-proBNP levels, consistently
across the three studies. Although these haplotypes were not
solely tagged by SNPs in or around NPPB, the G allele of
rs6676300, located near the promoter of NPPB, was present
in all four haplotypes. This could support rs6676300 as the
best proxy of a functional SNP for NPPB expression. Haplo-
types carrying the rs6676300 G allele not associated with
NT-proBNP were also observed, although it is possible that
this lack of association may be due to the low power of
these low-frequency haplotypes. On the other hand,
rs6676300 showed only modest association with BNP in the
Framingham Heart Study (16), which was not robust to adjust-
ment for nearby SNPs.
The genetically derived differences in NT-proBNP levels
were substantial in all three of our studies: individuals carrying
two copies of the associated haplotypes showed an increase in
the median NT-proBNP level between 20 and 100 pg/ml in
different populations, compared with the reference group car-
rying no copies of these four haplotypes. This variation rep-
resents an important finding, particularly if we consider that
the proportion of individuals carrying two copies of the four
haplotypes was substantial in our populations: 2.0, 2.6 and
4.7% in KORA-F3, MICROS and popgen, respectively.
These findings call for further research to evaluate a possible
predictive role of these haplotypes in the identification of
patients at risk of heart failure.
The availability of SNPs imputed on the same HapMap–
CEU data release was at the same time a strength and a limit-
ation for our fine-mapping analysis. The strength was that the
imputation based on the same map enabled a direct comparison
of results across studies. The limitation was that some of the
imputed SNPs had suboptimal imputation quality, which trans-
lates into measurement error affecting both SNP-based and
haplotype-based analyses. This non-differential measurement
error is known to bias the results towards the null (24) and
might have had some impact on our findings from both the
conditional and the haplotype analysis.
Although not surviving Bonferroni correction for claiming
replication, two SNPs in the MEIS1 and NR2F1 (also known
as COUP-TF1) genes showed promising findings, with repli-
cation P-values reaching nominal significance and P-values
of the combined analysis being smaller than those of the
discovery analysis (Table 2). The biological plausibility of
these findings (25–27) makes them worth further investi-
gation.
From a methodological point of view, our study highlighted
an interesting problem in the analysis of quantitative traits,
namely laboratory assay limit of detection (LOD). Although
censored data due to the presence of an LOD are not uncom-
mon in GWA analyses of quantitative traits, an adequate mod-
elling of such data has rarely been performed. In our MICROS
GWA study, nearly one-fifth of individuals had NT-proBNP
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values below the LOD, which was addressed by modelling the
logarithm of NT-proBNP with a Tobit model (28), assuming a
Weibull distribution of the trait. Compared with the naı¨ve
approach of excluding samples below the LOD, or of imputing
missing values by a fixed NT-proBNP level (LOD or LOD/2),
the Tobit method can protect not only against bias (29) but
also against a considerable loss of power. In fact, the results
from our MICROS study were consistent with those from
the replication studies, where data censoring was not present
due to the use of a different laboratory method.
In conclusion, our study identifies variants within the
MTHFR-CLCN6-NPPA-NPPB gene cluster that associate
with regulation of NT-proBNP levels. The association of
SNPs in the CLCN6 gene surviving the adjustment for
NPPB and NPPA variants suggests a potentially independent
role of CLCN6 in the regulation of NT-proBNP levels. The
identification of haplotypes in this gene cluster with substan-
tial effects on NT-proBNP levels calls for future research to
further clarify the role of this locus in the regulation of
NT-proBNP.
MATERIALS AND METHODS
Written informed consent was obtained from all participants in
the studies involved in this work. All study protocols were
approved by the institutional ethical review committees of
the participating centres.
Individual study description
The MICROS study (discovery). The MICROS study is a
cross-sectional genetic study performed in South Tyrol
(Italy) in 2001–03 (17). Participants were recruited from
three villages (Stelvio, Vallelunga and Martello) located in
the Italian Alps, in a German-speaking region bordering
with Austria and Switzerland that experienced a prolonged
period of isolation from surrounding populations. Information
on the participants’ health status was collected through a stan-
dardized questionnaire. Laboratory data were obtained through
standard blood analyses. All DNA samples were genotyped on
Illumina Infinium HumanHap300 v2 SNP bead microarrays
according to the manufacturer’s instructions. Genotypes
were obtained using the proprietary Bead Studio software. A
total of 1334 individuals were suitable for analysis after data
cleaning: call rate ,98%, minor allele frequency (MAF)
,1% and Hardy–Weinberg equilibrium (HWE) test P-value
,10206. NT-proBNP levels were measured in 1325 subjects
using chemiluminescence immunoassay at the Institute for
Clinical Chemistry and Laboratory Medicine, University of
Regensburg, Germany.
The popgen biobank (replication). Data on German healthy
individuals were obtained from the ‘control’ group of the
popgen biobank (30). Genotyping was carried out as part of
the GWAS initiative of the German National Genome
Research Network (NGFN) and was performed by an Affyme-
trix service facility (South San Francisco, CA, USA), using the
Affymetrix Genome-Wide Human SNP Array 6.0 (1000K)
(Santa Clara, CA, USA). Genotype calling was carried out
using Affymetrix’s Birdseed v2 algorithm with the default
quality thresholds. Samples with .5% missing genotypes,
showing excess genetic dissimilarity to the remaining subjects,
or with evidence of a cryptic relatedness to other study partici-
pants, were removed. These quality control measures left 1213
samples for inclusion in the replication cohort. All sex assign-
ments could be verified by reference to the proportion of het-
erozygous SNPs on the X chromosome. NT-proBNP was
assessed in 1152 serum samples with the elecsys NT-proBNP
assay (Roche Diagnostics) at the Institute for Clinical Chem-
istry in Kiel, Germany.
The KORA-F3 survey (replication). The KORA-F3 surveys for
genetic research, described in detail elsewhere (31,32), were
initiated as part of the MONICA (Monitoring of Trends of
Cardiovascular Diseases) multi-centre study. The third
KORA survey (KORA-S3) is a population-based sample
from the general population of the south German city of Augs-
burg and surrounding counties recruited in 1994–95. A sub-
sample consisting of 1644 individuals from this survey with
10-year follow-up information available (KORA-F3) was
successfully genotyped with the 500K Affymetrix Chip
(per-sample call rate .93%). All participants were German
citizens of European origin. NT-proBNP was assessed in
deep frozen (2808C) serum samples with the elecsys
NT-proBNP assay (Roche Diagnostics) in 594 samples. The
analytical range is 5–35 000 pg/ml and the coefficient of vari-
ation is ,10%.
Genotype imputation
Using the Phase II CEU HapMap individuals as a reference
panel (release 22, build 36), genotypes were imputed for
each study (MICROS, popgen and KORA-F3) for the entire
set of polymorphic HapMap SNPs (.2.5 million SNPs),
using a hidden Markov model as implemented in the MACH
software version 1.0.15/16 (33) (http://www.sph.umich.edu/
csg/abecasis/MACH/). At each marker, imputation results
were summarized as an ‘allele dosage’, defined as the
expected number of copies of the minor allele, which can
vary between 0 and 2. The Rsq statistic was estimated at
each SNP as the ratio of the observed variance of the allele
dosage (imputed value) to the expected variance under HWE
(34). Consequently, Rsq reflects possible deviations from
HWE and imputation quality. SNPs with Rsq ≤ 0.3, indicating
low-quality imputation, were discarded. Information on geno-
typing platforms and imputation performance is summarized
in Supplementary Material, Table S4.
Statistical analysis
In the discovery study, the diagnostic assay for assessing the
NT-proBNP level had an LOD equal to 20 pg/ml. Consequently,
the NT-proBNP level had to be considered a left-censored pheno-
type. Given that 18% of observations were below the LOD, the
use of conventional statistical methods could have led to biased
estimates in a regression analysis (35). We therefore fitted a
Tobit model to the loge(NT-proBNP) values, making the assump-
tion that loge(NT-proBNP) had a Weibull density function (28).
The LOD was loge-transformed accordingly. The model was
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adjusted for age, sex and study village. Briefly, under the
assumption of the data distribution, the Tobit procedure com-
putes the probability that a value is censored and uses this
probability to guide the estimation of the regression coeffi-
cients via maximum likelihood. Estimates obtained with the
likelihood-based method are less biased than those obtained
with other methods (29), thereby ensuring normality of the
regression residuals. To account for any inter-individual relat-
edness of MICROS participants, a polygenic linear model was
fitted to estimate the inverse of the variance/covariance matrix,
based on the genomic kinship matrix (36) and using the
GenABEL package (37). GWA between residuals of the
Tobit model and SNP dose levels was assessed by means of
an approximate score test statistic (38), using probABEL soft-
ware (http://mga.bionet.nsc.ru/~yurii/ABEL/) and assuming
an additive model of inheritance. To account for the number
of independent tests that could be performed on a (potentially)
infinitely dense genetic map, the threshold for claiming
genome-wide significance was set to 7.2 × 10208 (18). To
assess the possible impact of pharmacological treatment on
our GWA results, three sensitivity analyses were performed,
each time excluding a given group of individuals by consider-
ing the possible effect of such drugs on NT-proBNP levels,
according to Troughton et al. (39): (i) reduction (n ¼ 214,
16% of individuals); (ii) increase (n ¼ 72, 5%); (iii) alteration,
that is, either reduction or increase (n ¼ 286, 22%). The
excluded drugs with a potential ‘stimulating’ effect on
NT-proBNP levels were: antihypertensives, antithrombotic
agents, platelet aggregation inhibitors (aspirin), selective
beta-2-adrenoreceptor agonists (Salbutard), digoxin and beta-
blocking agents. Drugs that could reduce the NT-proBNP
level included agents acting on the renin–angiotensin system
(65% of ACE-inhibitors), anti-gout treatment (Allopulinor),
lipid-modifying agents, vasodilator-nitrates, sex hormones,
anti-arrhythmics, diuretics, peripherical vasodilators and
alpha- and beta-blocking agents (Carvedilol).
Replication analysis
Replication of our most promising findings was attempted in
two independent samples from the general population of two
German regions, which share much of their ethnic background
with the South Tyrol population in Italy. From the discovery
GWA analysis, SNPs withP-values,10205 were selected, pro-
vided that at least one more SNP with P-value ,10204 was
located within 100 kb. From these SNPs, independent loci
were identified based on LD, with independence defined by
pairwise r2 ,0.2. One SNP per locus was chosen and, after
accounting for multiple testing, SNPs with power to replicate
,80% were excluded. Power estimates were obtained with
QUANTO (40) (http://hydra.usc.edu/GxE/), assuming a repli-
cation sample size of 1746 individuals (sum of popgen and
KORA-F3), an additive genetic model and HWE.
In popgen and KORA-F3, SNP dose levels were tested for
an association with loge(NT-proBNP), using an ordinary
linear regression model, adjusted for age and sex, using
ProbABEL for popgen and MACH2QTL (http://www.sph.
umich.edu/csg/abecasis/MACH/) for KORA-F3. Regression
coefficients and SEs from individual replication studies were
pooled using an inverse-variance-weighted fixed-effect
meta-analysis, using the metafor R package (http://www.
wvbauer.com/downloads.html). Associations were considered
replicated if the direction in the replication analysis was the
same as in the discovery analysis and the one-sided P-value
was ,0.002, corresponding to 0.05 divided by the number
of SNPs tested, n ¼ 25 (Bonferroni correction).
To improve the precision of effect estimates, the effect esti-
mates of the SNPs submitted to replication were pooled across
the three studies (MICROS, popgen and KORA-F3) by means
of an inverse-variance-weighted fixed-effect meta-analysis. To
account for potential differences in the effect sizes due to the
use of different laboratory assays in MICROS compared with
the German studies, a sensitivity analysis was performed
by meta-analysing P-values, using a sample-size-weighted
Z-score method, which accounts for effect direction,
implemented in METAL (41).
Fine mapping of the MTHFR-CLCN6-NPPA-NPPB gene
cluster association
To dissect the effects of single variants in the trait-associated
locus on chromosome 1 (map positions 11 759 037 to
11 851 482), the original list of 128 SNPs in the region was
reduced to 29 high-quality SNPs that satisfied all of the fol-
lowing criteria: (i) present in all the three studies as either gen-
otyped or imputed; (ii) genotyped in at least one of the three
studies; (iii) if not genotyped, a high imputation quality
(Rsq. 0.6); (iv) P-value of association ≤0.05 in at least one
of the three studies (non-null effect size). The list was
further reduced after removing seven SNPs that were in
perfect LD with other SNPs from the list (r2. 0.98). The
final selection included 22 SNPs (see Supplementary Material,
Table S2, for the complete list of SNPs along with their impu-
tation quality). The number of SNPs genotyped versus
imputed was 15 versus 7, 12 versus 10 and 7 versus 15, in
MICROS, popgen, and KORA-F3, respectively. Of these 22
SNPs, 7 were located in the MTHFR gene, 8 in the CLCN6
gene, 2 in the NPPA gene and 5 in the NPPB gene.
To assess which SNPs were independently associated with
NT-proBNP, we fitted the following four linear regression
models to the loge(NT-proBNP) value for each of the 22
SNPs, using the allele dosage of the SNP as an influential
variable:
(i) adjusting for age and sex alone;
(ii) adjusting for age, sex, plus all SNPs belonging to the
second gene in the cluster;
(iii) adjusting for age, sex, plus all SNPs belonging to the
third gene in the cluster;
(iv) adjusting for age, sex, plus all SNPs belonging to the
fourth gene in the cluster.
To account for inter-individual relatedness in the MICROS
study, linear mixed models were fitted to the residuals
obtained from the regression of NT-proBNP on age and sex.
Results from all studies were pooled using an
inverse-variance-weighted fixed-effect meta-analysis. Given
that the 22 SNP considered were in LD, adjustment for mul-
tiple comparisons was performed according to Nyholt (42)
based on the observed LD pattern within each population.
The resulting threshold for statistical significance was 0.003.
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The same 22 SNPs were included in study-specific haplotype
analyses, using the haplo.stats R package (43) (http://mayo
research.mayo.edu/mayo/research/schaid_lab/software.cfm),
assuming an additive model of inheritance. Results were
pooled using an inverse-variance-weighted fixed-effects
meta-analysis.
If not specified otherwise, data management, data analysis,
programming and the creation of graphs were all performed
using R 2.9.2 (R Development Core Team 2009) (http://www.
R-project.org).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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